According to the 2014 European Society of Cardiology Guidelines, cardiomyopathies are defined as structural andfunctional abnormalities of the ventricular myocardium that are unexplained by flow limiting coronary artery diseaseor abnormal loading conditions. There are four major classifications of cardiomyopathy: hypertrophic (HCM), dilated(DCM), restrictive (RCM), and arrhythmogenic right ventricular (ARVC).
Familial cardiomyopathies (FCM) are most commonly diagnosed, or progress of the disease is monitored, throughin vivo imaging, with either echocardiography or, increasingly, cardiac magnetic resonance imaging (MRI). Thetreatment of symptoms of FCM by established therapies could only in part improve the outcome, but novel therapiesneed to bedeveloped to affect the disease process and time course morefundamentally.
SILICOFCM project will develop in silico computational cloud platform which will integrate from stopped-flowmolecular kinetic assays to magnetic resonance imaging of the whole heart, bioinformatics and image processing toolswith state of the art computer models with the aim toreduce animal and clinical studies for a new drug developmentandoptimized clinical therapy of FCM.
The developed system will be distributed on the cloud platforms in order to achieve efficient data storage and highperformancecomputing, that can offer end users results in reasonably short time. Academic technical partners IIT, UOI, UL and BSC will be responsible for developing and integration of in silico cloud computational platform with multi-scale cardiac muscle modelling which include experiments on protein mutation in vitro from UNIKENT, UNIFI and UW. Bioinformatics tools will be integrated by US company SBG. Clinical partners UNEW, ICVDV and UHREG will do retrospective and prospective studies. SME partner R-Tech will be incharge of regulatory issues andreports and BIOIRC will do the exploitation of the project.